About: EMA must improve the quality of its clinical trial reports

Documentation

scienceplus.abes.fr version Bêta

scienceplus.abes.fr | explorer

À propos de : EMA must improve the quality of its clinical trial reports Goto Sponge NotDistinct Permalink

Attributs	Valeurs
type	work Article
Is Part Of	http://hub.abes.fr/bmj/periodical/bmj/2011/volume_342/issue_2011/w
Subject	analysis
Title	EMA must improve the quality of its clinical trial reports
has manifestation of work	http://hub.abes.fr/bmj/periodical/bmj/2011/volume_342/issue_2011/B36EB45E705A18DEE053120B220A8BFE/m/web http://hub.abes.fr/bmj/periodical/bmj/2011/volume_342/issue_2011/B36EB45E705A18DEE053120B220A8BFE/m/print
related by	http://hub.abes.fr/bmj/periodical/bmj/2011/volume_342/issue_2011/B36EB45E705A18DEE053120B220A8BFE/authorship/1 http://hub.abes.fr/bmj/periodical/bmj/2011/volume_342/issue_2011/B36EB45E705A18DEE053120B220A8BFE/authorship/2 http://hub.abes.fr/bmj/periodical/bmj/2011/volume_342/issue_2011/B36EB45E705A18DEE053120B220A8BFE/authorship/3
Abstract	Corrado Barbui, Cinzia Baschirotto, and Andrea Cipriani find that the results of phase III studies are poorly and inconsistently documented in the EMA’s drug assessment reports. Better reporting would make them more useful for doctors, researchers, and consumers
article type	other
publisher identifier	barc843904
is part of this journal	British Medical Journal

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata